Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
By Gregg Stone, B. Witzenbichler, G. Weisz, M. Rinaldi, F. Neumann, C. Metzger, T. Henry, D. Cox, Peter L Duff, E. Mazzaferri and 7 more. The Lancet, 2013
804 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology, Oncology
View Paper: https://www.semanticscholar.org/paper/c8cfdb9e4ffee4d1dd297dc781a2b3f437207b4a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. (2016, methodology): “The ADAPT-DES study([14]) investigated the relationship between high platelet reactivity (HPR) on clopidogrel (HPR 4,930 patients, not HPR 3,650 patients) to stent thrombosis and other cardiovascular events at 12 months follow-up in a prospective, multicentre registry of patients receiving drug-elut”
- Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. (2013, methodology): “The authors observed that HPR had a greater impact in ACS patients than in stable coronary artery disease (CAD) patients (16).”